Stuttgart - Delayed Quote EUR

Abivax SA (2X1.SG)

6.60
-0.58
(-8.08%)
At close: June 10 at 9:41:47 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Cost of Revenue
--
--
--
50,764
45,517
Gross Profit
--
--
--
-50,764
-45,517
Operating Expense
175,513
172,984
127,377
51,205
41,398
Operating Income
-175,513
-172,984
-127,377
-51,205
-41,398
Net Non Operating Interest Income Expense
-7,682
-4,564
-12,708
-6,717
-3,476
Other Income Expense
-2,548
1,307
-7,654
-2,820
2,425
Pretax Income
-185,745
-176,242
-147,740
-60,740
-42,452
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-185,745
-176,242
-147,740
-60,740
-42,452
Diluted NI Available to Com Stockholders
-185,745
-176,242
-147,740
-60,740
-42,452
Basic EPS
-2.95
-2.80
-3.43
-3.18
-2.75
Diluted EPS
-2.95
-2.80
-3.43
-3.18
-2.75
Basic Average Shares
63,161.69
63,046.35
43,066.01
19,092.44
15,455.99
Diluted Average Shares
63,161.69
63,046.35
43,066.01
19,092.44
15,455.99
Total Operating Income as Reported
-175,513
-172,984
-127,376
-64,836
-41,400
Rent Expense Supplemental
482
--
--
1,048
548
Total Expenses
175,513
172,984
127,377
51,205
41,398
Net Income from Continuing & Discontinued Operation
-185,745
-176,242
-147,740
-60,740
-42,452
Normalized Income
-187,186
-178,916
-136,888
-56,474
-44,877
Interest Income
7,293
8,956
2,773
0
0
Interest Expense
14,542
12,431
13,826
6,940
3,558
Net Interest Income
-7,682
-4,564
-12,708
-6,717
-3,476
EBIT
-171,203
-163,811
-133,914
-53,800
-38,894
EBITDA
-170,041
-162,711
-133,207
-53,315
-38,592
Reconciled Cost of Revenue
--
--
--
50,526
45,517
Reconciled Depreciation
1,162
1,100
707
485
302
Net Income from Continuing Operation Net Minority Interest
-185,745
-176,242
-147,740
-60,740
-42,452
Total Unusual Items Excluding Goodwill
1,441
2,674
-10,852
-4,266
2,425
Total Unusual Items
1,441
2,674
-10,852
-4,266
2,425
Normalized EBITDA
-171,482
-165,385
-122,355
-49,049
-41,017
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 8/28/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TRGNF Transgene SA
2.0000
+185.71%
 
MOLN Molecular Partners AG
3.6967
-4.85%
 
AVBP ArriVent BioPharma, Inc.
24.50
+3.81%
 
GHRS GH Research PLC
12.84
-6.28%
 
TCRX TScan Therapeutics, Inc.
1.6900
-4.52%
 
GUTS Fractyl Health, Inc.
2.1600
-25.00%
 
BNTX BioNTech SE
106.89
-1.91%
 
MRNA Moderna, Inc.
27.68
-1.63%